Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
The synthesis and structure-activity relationship of a novel series of compounds with combined effects on 5-HT(3A) and 5-HT(1A) receptors and on the serotonin (5-HT) transporter (SERT) are described. Compound 5m (Lu AA21004) was the lead compound, displaying high affinity for recombinant human 5-HT(1A) (K(i) = 15 nM), 5-HT(1B) (K(i) = 33 nM), 5-HT(3A) (K(i) = 3.7 nM), 5-HT(7) (K(i) = 19 nM), and noradrenergic β(1) (K(i) = 46 nM) receptors, and SERT (K(i) = 1.6 nM). Compound 5m displayed antagonistic properties at 5-HT(3A) and 5-HT(7) receptors, partial agonist properties at 5-HT(1B) receptors, agonistic properties at 5-HT(1A) receptors, and potent inhibition of SERT. In conscious rats, 5m significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment. Following the 3-day treatment (5 or 10 (mg/kg)/day) SERT occupancies were only 43% and 57%, respectively. These characteristics indicate that 5m is a novel multimodal serotonergic compound, and 5m is currently in clinical development for major depressive disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The in vivo nonclinical studies in rodents have demonstrated that vortioxetine modulates serotonergic, noradrenergic, dopaminergic, cholinergic, histaminergic, and glutamatergic neurotransmission, affecting the levels of neurotransmitters involved in cognitive processes (Bang-Andersen et al, 2011; Mork et al, 2012, 2013; Pehrson et al, 2013; Pehrson and Sanchez, 2014; Wallace et al, 2014).”
From A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder (2015) · cites this paper as Bang-Andersen et al, 2011
In the citing paper
“The antidepressant vortioxetine, developed by Lundbeck and Takeda and approved in 2013, is a 5-HT 3 , 5-HT 7 and 5-HT 1D receptor antagonist, a 5-HT 1B receptor partial agonist, a 5-HT 1A receptor agonist and an inhibitor of the 5-HT transporter (Bang-Andersen et al., 2011) with a good tolerability and long-term safety profile and no evidence of sexual dysfunction as a side effect.”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Bang-Andersen et al., 2011
In the citing paper
“Vortioxetine (Lu AA21004) is an antidepressant that acts as an antagonist of the 5-HT3 and 5-HT7 serotonin receptors, partial agonist of the 5-HT1B serotonin receptor, agonist of the 5-HT1A receptor, and inhibits the serotonin transporter [88].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [88]
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
Fanselow, M. S., & Dong, H.-W. (2010) · Neuron · doi:10.1016/j.neuron.2009.11.031 · Cited by 3,358
Drevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241
Evidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Rankovic, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,209
A Simple Catalytic Method for the Conversion of Aryl Bromides to Arylamines
Guram, A. S., Rennels, R. A., & Buchwald, S. L. (1995) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199513481 · Cited by 1,070
Louie, J., & Hartwig, J. F. (1995) · Tetrahedron Letters · doi:10.1016/0040-4039(95)00605-c · Cited by 914
Is there a role for 5-HT1A agonists in the treatment of depression?
Blier, P., & Ward, N. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01643-8 · Cited by 529
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Artigas, F. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030084009 · Cited by 510
Scope and Limitations of the Pd/BINAP-Catalyzed Amination of Aryl Bromides
Wolfe, J. P., & Buchwald, S. L. (2000) · The Journal of Organic Chemistry · doi:10.1021/jo9916986 · Cited by 438
Cory Kalvass, J., & Maurer, T. S. (2002) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.325 · Cited by 412
Long-Term Antidepressant Treatments Result in a Tonic Activation of Forebrain 5-HT1AReceptors
Haddjeri, N., Blier, P., & de Montigny, C. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-23-10150.1998 · Cited by 332
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308
Sánchez, C., Bergqvist, P. B. F., Brennum, L. T., Gupta, S., Hogg, S., Larsen, A., & Wiborg, O. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1364-z · Cited by 265
Self-citationThe pharmacology of putative early-onset antidepressant strategies
Blier, P. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00173-6 · Cited by 244
Novel Drugs and Therapeutic Targets for Severe Mood Disorders
Mathew, S. J., Manji, H. K., & Charney, D. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301652 · Cited by 223
Gardier, A., Malagié, I., Trillat, A., Jacquot, C., & Artigas, F. (1996) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.1996.tb00145.x · Cited by 197
Millan, M. J. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.039 · Cited by 196
A general palladium-catalysed synthesis of aromatic and heteroaromatic thioethers
Schopfer, U., & Schlapbach, A. (2001) · Tetrahedron · doi:10.1016/s0040-4020(01)00157-0 · Cited by 195
Bauer, M., Monz, B. U., Montejo, A. L., Quail, D., Dantchev, N., Demyttenaere, K., Garcia-Cebrian, A., Grassi, L., Perahia, D. G. S., Reed, C., et al. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2007.11.001 · Cited by 186
Selective Activation of Postsynaptic 5-HT1A Receptors Induces Rapid Antidepressant Response
Blier, P. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00242-4 · Cited by 184
Differentiating antidepressants of the future: Efficacy and safety
Rosenzweig-Lipson, S., Beyer, C. E., Hughes, Z. A., Khawaja, X., Rajarao, S. J., Malberg, J. E., Rahman, Z., Ring, R. H., & Schechter, L. E. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.07.002 · Cited by 179
Bonaventure, P., Kelly, L., Aluisio, L., Shelton, J., Lord, B., Galici, R., Miller, K., Atack, J., Lovenberg, T. W., & Dugovic, C. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.119404 · Cited by 169
Mørk, A., Kreilgaard, M., & Sánchez, C. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00138-2 · Cited by 163
Self-citationInactivation of 5-HT2C Receptors Potentiates Consequences of Serotonin Reuptake Blockade
Cremers, T. I. F. H., Giorgetti, M., Bosker, F. J., Hogg, S., Arnt, J., Mørk, A., Honig, G., Bøgesø, K.-P., Westerink, B. H. C., den Boer, H., et al. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300474 · Cited by 157
Self-citationMorales, M., Battenberg, E., de Lecea, L., & Bloom, F. E. (1996) · Brain Research · doi:10.1016/0006-8993(96)00557-4 · Cited by 145
The 5-HT7 receptor as a mediator and modulator of antidepressant-like behavior
Sarkisyan, G., Roberts, A. J., & Hedlund, P. B. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.01.022 · Cited by 122
Noradrenaline in mood and anxiety disorders: basic and clinical studies
Brunello, N., Blier, P., Judd, L. L., Mendlewicz, J., Nelson, C. J., Souery, D., Zohar, J., & Racagni, G. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200307000-00001 · Cited by 121
Beyer, C. E., Boikess, S., Luo, B., & Dawson, L. A. (2002) · Journal of Psychopharmacology · doi:10.1177/026988110201600403 · Cited by 114
Pindolol Augmentation of Antidepressant Response
Artigas, F., Adell, A., & Celada, P. (2006) · Current Drug Targets · doi:10.2174/138945006775515446 · Cited by 111
Yan, Z. (2002) · Molecular Neurobiology · doi:10.1385/mn:26:2-3:203 · Cited by 100
Depression and nicotine: preclinical and clinical evidence for common mechanisms
Laje, R. P., Berman, J. A., & Glassman, A. H. (2001) · Current Psychiatry Reports · doi:10.1007/s11920-001-0040-z · Cited by 74
Farde, L., Ginovart, N., Ito, H., Lundkvist, C., Pike, V. W., McCarron, J. A., & Halldin, C. (1997) · Psychopharmacology · doi:10.1007/s002130050391 · Cited by 72
Owens, M. J., Krulewicz, S., Simon, J. S., Sheehan, D. V., Thase, M. E., Carpenter, D. J., Plott, S. J., & Nemeroff, C. B. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.47 · Cited by 68
Matsumoto, M., Yoshioka, M., Togashi, H., Tochihara, M., Ikeda, T., & SAITO, H. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24527-x · Cited by 61
Assié, M. B., Lomenech, H., Ravailhe, V., Faucillon, V., & Newman‐Tancredi, A. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706859 · Cited by 61
Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.7.1084 · Cited by 58
Serotonergic Modulation of Acetylcholine Release from Cortex of Freely Moving Rats
Giovannini, M. G., Ceccarelli, I., Molinari, B., Cecchi, M., Goldfarb, J., & Blandina, P. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37512-3 · Cited by 55
Moltzen, E. K., & Bang‐Andersen, B. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606778249810 · Cited by 52
Self-citationThe future of psychopharmacology of depression.
Chang, T., & Fava, M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06223blu · Cited by 50
Beyond psychoanaleptics – can we improve antidepressant drug nomenclature?
Nutt, D. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109105498 · Cited by 48
Occupancy of Agonist Drugs at the 5-HT1A Receptor
Bantick, R. A., Rabiner, E. A., Hirani, E., de Vries, M. H., Hume, S. P., & Grasby, P. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300390 · Cited by 48
Angel, I., Schoemaker, H., Prouteau, M., Garreau, M., & Langer, S. Z. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90767-c · Cited by 41
Sánchez, C., Brennum, L. T., Stórustovu, S. Í., Kreilgaard, M., & Mørk, A. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.01.006 · Cited by 38
Self-citationWong, H., Dockens, R. C., Pajor, L., Yeola, S. N., Grace, J. E., Stark, A. D., Taub, R. A., Yocca, F. D., Zaczek, R. C., & Li, Y. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015768 · Cited by 36
Palladium-catalyzed monoamination of dihalogenated benzenes
Larsen, S. B., Bang‐Andersen, B., Johansen, T. N., & Jørgensen, M. (2008) · Tetrahedron · doi:10.1016/j.tet.2008.01.070 · Cited by 29
Self-citationLarsen, A. K., Brennum, L. T., Egebjerg, J., Sánchez, C., Halldin, C., & Andersen, P. H. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705693 · Cited by 28
Iron-Assisted Nucleophilic Aromatic Substitution on Solid Phase
Ruhland, T., Bang, K. S., & Andersen, K. V. (2002) · The Journal of Organic Chemistry · doi:10.1021/jo025721q · Cited by 27
Self-citationYamada, Y., Sugiura, M., 肥後, こ., Ozeki, T., Takayanagi, R., Okuyama, K., Yamamoto, K., Satoh, H., Sawada, Y., & Iga, T. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0798-x · Cited by 24
Role of extracellular serotonin levels in the effect of 5-HT1B receptor blockade
de Groote, L., Klompmakers, A. A., Olivier, B., & Westenberg, H. G. M. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1371-0 · Cited by 21
Gray, D. L., Xu, W., Campbell, B. M., Dounay, A. B., Barta, N. S., Borosky, S., Denny, L. I., Evans, L. M., Stratman, N. C., & Probert, A. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.10.014 · Cited by 15
Mørk, A., Brennum, L. T., Fallon, S., Bisulco, S., Frederiksen, K., Bang‐Andersen, B., Lassen, A. B., Zhong, H., Sanchez, C., & Stensbøl, T. B. (2009) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(09)70683-2 · Cited by 11
Self-citationP.2.b.015 Lu AA21004: a novel potential treatment for mood disorders
Moore, N., Bang‐Andersen, B., Brennum, L. T., Fredriksen, K., Hogg, S. L., Mørk, A., Stensbøl, T. B., Zhong, H., Sanchez, C., & Smith, D. T. (2008) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(08)70440-1 · Cited by 9
Self-citationANTINEOPLASTIC AGENTS: XI. N-BIS(2-BROMOETHYL)AMINES
Pettit, G. R., Chamberland, M. R., Blonda, D. S., & Vickers, M. A. (1964) · Canadian Journal of Chemistry · doi:10.1139/v64-253 · Cited by 8
Research works printed but not linked: 3
- Lenox R. H., 2002, Neuropsychopharmacology: The Fifth Generation of Progress: An Official Publication of the American College of Neuropsychopharmacology, 1139
- Moore N. A., 2008, Neuropsychopharmacology, 18, S321, 10.1016/s0924-977x(08)70440-1 · DOI
- Brunello N., 2003, Int. Clin. Psychopharmacol., 18, 191, 10.1097/01.yic.0000073880.93678.68 · doi:10.1097/01.yic.0000073880.93678.68 · Paper page
Cited by
SLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 864
Monoamine neurocircuitry in depression and strategies for new treatments
Hamon, M., & Blier, P. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.04.009 · Cited by 594
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
“Specifically, vortioxetine is a serotonin 5-HT1A receptor agonist, 5-HT1B receptor partial agonist, 5-HT3A and 5-HT7 receptor antagonist, and a potent serotonin reuptake inhibitor (Bang-Andersen et al., 2011; Mork et al., 2012).”
BackgroundMethodSanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
“It was also thought that 5-HT3 receptor antagonism might reduce the incidence of nausea observed during treatment with SSRIs and serotonin and noradrenaline reuptake inhibitors (SNRIs) (Bang-Andersen et al., 2011).”
BackgroundMethodInfluentialMcIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
“: +1 -416-603-5279 Fax: +1-416-603-5368 Email: roger.mcintyre@uhn.ca and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist, and a 5-HT transporter inhibitor (Bang-Andersen et al., 2011; Mørk et al., 2012; Westrich et al., 2012).”
Background
Metadata
- Authors
- Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., & Stensbøl, T. B.
- Affiliations
- Neuroscience Drug Discovery Denmark, H. Lundbeck A/S, 9 Ottiliavej, DK-2500 Copenhagen-Valby, Denmark
- Lundbeck (Denmark) (DK)
- Lundbeck (United States) (US)
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-04-12
- Volume
- 54
- Issue
- 9
- Pages
- 3206-3221
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2036812642
- Cited by
- 606
- References
- 58
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 24 · 2023: 33 · 2022: 27 · 2021: 27 · 2020: 181 · 2019: 32 · 2018: 21 · 2017: 37 · 2016: 37 · 2015: 53 · 2014: 35 · 2013: 25 · 2012: 21
- FWCI
- 21.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- vortioxetine, major depressive disorder, multimodal antidepressant, 5-HT3 receptor antagonists, 5-HT1A receptor, 5-HT1B receptor, 5-HT7 receptor, serotonin transporter inhibition, structure-activity relationship, piperazine derivatives
- MeSH terms
- Vortioxetine, Animals, Antidepressive Agents, Cell Line, Major Depressive Disorder, Depressive Disorder, Major, Drug Stability, Hippocampus, Humans, Microsomes, Liver, Oocytes, Piperazines, Radioligand Assay, Receptors, Serotonin, Recombinant Proteins, Serotonin, Structure-Activity Relationship, Sulfides, Xenopus, Selective Serotonin Reuptake Inhibitors, Receptors, Serotonin, 5-HT1, Receptor, Serotonin, 5-HT1A, Receptor, Serotonin, 5-HT2C, Receptors, Serotonin, 5-HT3, Serotonin Plasma Membrane Transport Proteins, Rats, Drug Partial Agonism, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT3 Receptor Antagonists, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.